Member Info for Diversified

When you look at Pre and it’s performance/market cap now exceeding £200m with less money in the bank and located in Angola. Although the material is different, the projected growth in demand is similar.

I think you can look to Pre share price as a similar precursor to what will happen to the share price here! At some point in the near future it will make a stride forward on no news but to its next technical point of 78.5p and even then it would have lower market cap than Pre. Pre increase 30% yesterday alone.

When you look at it’s peers, yes they are further down the development curve but equally the market cap is 7/8x that of BCN, it speaks volumes for how under the radar this stock is.

With the company confirming by way of a recent interview that it already has the funds in place for the construction of the mine. Q1 will reveal the America investors that will see this deposit close to their border as a strategic asset.

I have said on another board, that I don’t think it will be long before the company is subject to a hostile bid from Ganfeng as the structure of the current deal is 50/50. Interestingly Lithium America retained a 51/49 interest.

One of those is a one of my buys, not all of, if any were sells. You couldn’t even buy any for the last 15 minutes and could sell on the ask as many as you wanted.

I did find it strange that the Supreme Court had ruled in favor of BKY a week earlier than Fridays press release and yet the company didn’t find it as grounds for an RNS. Today we could also see that this news was secondary to the most important update which confirmed that the NSC I will be in place for as long as it takes to get NSC II. All of which is favorably staking in favor of BKY, with a depressed European Economy only adding further fuel to the fire for local job creation.

Very encouraging.

When looking at industry sentiment such as NCYT performance today it won’t take long for that to transfer here. We should be at 170+ levels imo as if you truly believe the company will deliver like I do, we are working from a very low historical (Covid related) base.

Big returns for those with patience imo!

It’s all their in the RNS,

- A highly scalable test device using ‘readily available components’ and routine manufacturing processes

Readily available components, nothing complicated here from BBI

- The performance of the test with clinical samples will now be evaluated as a precursor to a much larger clinical study with COVID-19 patients of known viral load to determine the clinical sensitivity of the test.

With AI confirming in his director interview that the clinical study has already been put in place, thus a date is likely along the project timeline.

With the UK government then hopeful of putting BAMS testing in place in December as per the head of the trials communicated on Twitter, we have plenty of newsflow to come on all fronts and impatient robinhood investors or bitter bystanders will watch it unfold.

I think the Nasdaq and this link indicates the true value and future potential scale of Avacta’s therapeutic division:

https://investingnews.com/daily/life-science-investing/biotech-investing/top-oncology-companies/

Given earlier comments from 2019 that implied that they may consider splitting the diagnostics and therapeutic divisions, it is one way of minimizing dilution by listing the therapeutic division on the Nasdaq. It will also serve the purpose of reducing Covid sentiment from the core business.

Imo, the underlying strength in the share price is indicative of the share price now representing very little value for the diagnostics business as the higher market cap and subsequent raise that minimized dilution by comparison to what would of been the case had the share price not of rerated.

Covid has presented a whole new dynamic to the business model as it aims to show that the therapy will be safe in man. This will then lead to significant upfront payments from future collaborators/partners compared to what it has received to date.

For me, Avacta remains a sitting duck to one of the cash rich big boys and a takeover cannot be ruled out in the future.

We all know that the biotech/Pharma sector has now moved into Vogue and will remain popular for some time to come.

Newsflow over the course of the next several weeks will take the market cap to a new level imo.

Avacta IP is of extreme value and is now very much in the sectors sights.

They want all my stock, the hole lot. The demand is huge!

Wow, the strength and underlying/unreported demand for this stock over the last few days has been incredible.

This has to be institutional investors at play!

Mow - hot money.

Not referring to investors.

From forums like this to twitter, the general activity has fallen considerably as the hot money chases a new horizons.

Let’s not forget that the expectation of news from our last update grows every closer and our steadily increasing share price is starting to move before the event.

With news imminent on multiple fronts, anyone patiently waiting will be rewarded handsomely. Just think of the reaction to the share price when the Avacta test is being reported by mainstream media.

Our time is coming.

Volume was incredible in the auction and further volume was reported this morning from late yesterday.

Market makers are prepared to buy significant levels of stock off me this morning above bid as they must be trying to balance the books.

Technically the chart now looks very strong.

Today should be a very good day imo

That drop was short and shallow, Fcap May of just got aggressive and this will go blue Imo.

With 40% of the share register having been traded in the last 11 trading days we can be reasonably confident that the shareholder register would have got rid of many of the bed wetters, profit takers and bored shareholders and that new shareholders with new time frames/more patience/new share price targets are present.

I for one originally missed the extensive Covid gains and had been waiting for the share price to fall back as an opportunity to join the affair, and what a time to join.

Some will be hoping for the normal morning drop to buy slightly lower, but imo even if it comes, further new money is desperate to join the story at the business end of proceedings.

In conjunction with the AZN update which was a fairly immaterial event in terms of share price reaction, I think it’s fair to say that the market has now done a good job in forward pricing the best case scenario for future vaccine news. One could argue that the risk now lies to the upside as far as vaccine role out is concerned.

Risk: Neutral

BAMS test is making very good progress and various reports have suggested that the results are at least as good as a PCR test, but cheaper. Commercial progress is being made and evaluation is further down the line than I think many have given Avct credit for.

Risk: Low

Elisa test is also making good commercial progress and I believe will be announced in conjunction with the BAMS commercial agreement.

Risk: Low

Nasel LFT has achieved sensitivity within range and mass production. With many near term catalysts/milestones, a great addition to the product mix. When sensitivity and specificity is announced in conjunction with a wider trial, I expect this to gain significant traction as it fills the massive void in supply that is obviously apparent.

Risk: Neutral/Low

Saliva LFT, while great progress has been made it provides the greatest risk but perhaps the highest upside if it does achieve TT. Knowone is giving it any chance of success, for the right reasons? Maybe, maybe not.

Risk: High

My point being at the current market cap of £275m with net cash of £40/50m, the proposition is materially more attractive at 109p compared to 185p. With many near term catalysts likely to deliver a strong level of newsflow, yes I can understand the disappointment in terms of delays and empty promises, but at the same time the share price offers the greatest level of opportunity given the current risk profile.

Everything we hoped the government would introduce in terms of mass testing and the moonshot has been delivered, and more. It’s the perfect storm, we WILL have a number of tests, we have a secured a percentage of the sovereign supply chain, and we WILL generate significant revenue. It’s just a case of time.

This for me is not the time to be influenced by others and trade on emotions, my position is clear.

https://www.***************************/avacta-group-make-significant-progress-with-its-highly-scalable-lateral-flow-test-interview/412940598

Great progress made on saliva LFT alongside nasel
LFT which will provide direct competition to foreign LFT’s.

Also confirming that this is a very busy period for AVCT and therefore further material updates will drive the share price at the business end of product launches.

Seen this every day for two weeks now, fall wasn’t as much but that is a gift from the mm’s.

A direct competitor to the current LFT tests on the market. Made in England and less invasive.

BAMS also close to market that provide results similar to that of PCR testing but quicker and cheaper.

If I was to be worried I would be over at NCYT looking at AVCT as a massive threat to my market share. Luckily we need all the testing we can get, but when that market need reduces, the most competitive tests survive.

Welcome AVCT - we have an LFT test that can be mass produced. Massive tick.

It’s great to get an update, an update that further derisks the proposition and will no doubt be expanded on in an interview in the coming days.

Progress on all fronts and more importantly sensitivity within range for a product that can be mass produced.

Massive derisking event today and the share price is yet to reflect this due to the drop of two weeks ago. Back to £2 and above

Mapsciences have completed their MS validation, now awaiting approval. It can only be Avacta.

We didn’t get a speeding ticket on the way down and imo we are unlikely to get a speeding ticket on the way up, unless the share price was to move from here to ATH in one sharp sustained move over a short period.

Fact of the matter is, we have a significant number of updates pending:

- TT and professional use validation timelines
- BAMS validation results and commercial contract disclosure
- Confirmation of affirmer in house and external production expansion
- Increase in manufacturing capacity
- Submission of AVA for phase I trials

And without going over the top you get my point.

Now assuming they deliver, 100p and even 140p is to lower base to start from for all this news to drop as the risk reward is very attractive at these levels. When significant shareholder returns remain possible below a certain price (200p imo), the market will move before the event and allow the RNS to surprise to the upside as a derisking commercial event.

With the rise likely to continue to factor in the above, this is the reason for the move. We also know that the market has now priced in the vaccine news, yes the mm will continue to play games on vaccine updates but as per this mornings update from AZN, the reaction across the board was relatively muted.